Biocept Stock

Biocept Net Income

Delisted

The Net Income of Biocept (BIOC) as of Aug 12, 2026 is -32.09 M USD. In the previous year, Net Income was -2.82 M USD — a change of 1,036.23% (lower).

Net Income

-32.09 MUSD

YoY

1,036.23%

Last updated:

In 2026, Biocept's profit amounted to -32.09 M USD, a 1,036.23% increase from the -2.82 M USD profit recorded in the previous year.

The Biocept Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

NET INCOME (undefined USD)
Date
NET INCOME (undefined USD)
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
0.00 base
Jan 1, 2022
0.00 base
Jan 1, 2023 (e)
0.00 base
Jan 1, 2024 (e)
0.00 base
Jan 1, 2025 (e)
0.00 base
Jan 1, 2026 (e)
0.00 base
YEARNET INCOME (undefined USD)
2026 est -
2025 est -
2024 est -
2023 est -
2022 -
2021 -
2020 -
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
Access this data via the Eulerpool API

Biocept Revenue

Biocept Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
5.53 M USD
-23.06 M USD
-24.61 M USD
Jan 1, 2020
27.46 M USD
-15.47 M USD
-17.04 M USD
Jan 1, 2021
61.25 M USD
-2.41 M USD
-2.82 M USD
Jan 1, 2022
25.86 M USD
-31.98 M USD
-32.09 M USD
Jan 1, 2023 (e)
2.48 M USD
-24.44 M USD
-98.66 M USD
Jan 1, 2024 (e)
6.47 M USD
-23.53 M USD
-24.53 M USD
Jan 1, 2025 (e)
21.48 M USD
-15.82 M USD
-15.11 M USD
Jan 1, 2026 (e)
21.63 M USD
-3.19 M USD
-8.45 M USD

Biocept Margins

Biocept stock margins

The Biocept margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biocept. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biocept.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
-98.56 %
-417.05 %
-445.23 %
Jan 1, 2020
22.30 %
-56.33 %
-62.06 %
Jan 1, 2021
38.34 %
-3.93 %
-4.61 %
Jan 1, 2022
-9.99 %
-123.69 %
-124.09 %
Jan 1, 2023 (e)
-9.99 %
-985.41 %
-3,978.37 %
Jan 1, 2024 (e)
-9.99 %
-363.61 %
-379.17 %
Jan 1, 2025 (e)
-9.99 %
-73.64 %
-70.36 %
Jan 1, 2026 (e)
-9.99 %
-14.74 %
-39.08 %

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Net Income Details

Understanding Biocept's Profit Margins

The profit margins of Biocept represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Biocept's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Biocept's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Biocept's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Biocept’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Biocept stock

Net Income of Biocept is -32.09 M USD in 2026.

Net Income of Biocept changed from -2.82 M USD to -32.09 M USD, representing a 1,036.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Income Biocept since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's Biocept historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

Income Statement — Biocept

All Key Metrics — Biocept